Logo
x

Search

Subscribe Now

brca-mutated

AstraZeneca and MSD Report Five Year Data of Lynparza in P-III SOLO-1 Study for 1L Maintenance Treatment in Patients with BRCA-Mutated Ovarian Cancer

AstraZeneca and MSD Report Five Year Data of Lynparza in P-III SOLO-1 Study for 1L Maintenance Treatment in Patients with BRCA-Mut...

  • September 18, 2020
AstraZeneca and MSD's Lynparza (olaparib) Receives EC's Approval for BRCA-Mutated Metastatic Pancreatic Cancer

AstraZeneca and MSD's Lynparza (olaparib) Receives EC's Approval for BRCA-Mutated Metastatic Pancreatic Cancer

  • July 8, 2020
AstraZeneca's Lynparza (olaparib) Receives MHLW's Orphan Drug Designation for BRCA-Mutated Metastatic Pancreatic Cancer

AstraZeneca's Lynparza (olaparib) Receives MHLW's Orphan Drug Designation for BRCA-Mutated Metastatic Pancreatic Cancer

  • March 19, 2020
AstraZeneca and Merck &Co's Lynparza Receive the US FDA's Approval as a 1L Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer

AstraZeneca and Merck &Co's Lynparza Receive the US FDA's Approval as a 1L Maintenance Treatment of Germline BRCA-Mutated Metastat...

  • December 30, 2019
Pfizer's Talzenna (talazoparib) Receives European Commission Approval for Germline BRCA-Mutated Locally Advanced or Metastatic Breast Cancer

Pfizer's Talzenna (talazoparib) Receives European Commission Approval for Germline BRCA-Mutated Locally Advanced or Metastatic Bre...

  • June 24, 2019
AstraZeneca and MSD's Lynparza (olaparib) Receive European Commission's Approval as 1L Maintenance Treatment for BRCA-Mutated Advanced Ovarian Cancer

AstraZeneca and MSD's Lynparza (olaparib) Receive European Commission's Approval as 1L Maintenance Treatment for BRCA-Mutated Adva...

  • June 18, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.